A new Covid-19 therapy has completed its phase two human trial and the results are promising. Molnupiravir, developed by Ridgeback Biotherapeutics LP and Merck & Co., reached its endpoint objective of reducing the length of Covid-19 infections, accordi…
The dangers of relaxing Covid-19 restrictions are apparent in the rising numbers of new infections across Europe.
The B.1.1.7 variant is already known to be more transmissible, but according to new research, it is associated with 55% higher mortality too.
If we had a pancoronavirus vaccine, revising existing Covid-19 vaccines year in and year out wouldn’t be necessary. According to two new studies, nanoparticle immunization technology might be the key.
The results are encouraging, but we must err on the side of caution and conduct more elaborate studies before ruling that the first generation of vaccines is variant-proof.
Last year van Dissel downplayed the virus and promoted a herd immunity approach. Now he dons a mask in public, advises against loosening the lockdown reins until there is sustained improvement in Covid-19 indicators, and doesn’t talk about naturally ac…
Lung cancer, the 2nd-most common cancer and leading cause of cancer death in the United States, may see its numbers drop.
New data on the antibody-resistant Brazilian variant (P.1) can begin to shed light on a number of questions people may have. Can you get reinfected if you had a past infection and if you are reinfected, will you get sick?
Mental health professionals are finding themselves charged with the heavy responsibility of guiding others through this time of loss and uncertainty, without most of their usual coping mechanisms.
When it comes to T-cell immunity, responses to one form of the virus mean a high response to them all. Here we will review what that might mean for the future of Covid-19.
